A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
ensure that valid generic drugs may enter the market. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Fair And Immediate 
4
Release of Generic Drugs Act’’ or the ‘‘FAIR Generics 
5
Act’’. 
6
00:08 Mar 16, 2019
H1506
2 
•HR 1506 IH
SEC. 2. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS RE-
1
GARDING FIRST APPLICANT STATUS. 
2
(a) AMENDMENTS TO FEDERAL FOOD, DRUG, AND 
3
COSMETIC ACT.— 
4
(1) IN GENERAL.—Section 505(j)(5)(B) of the 
5
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
6
355(j)(5)(B)) is amended— 
7
(A) in clause (iv)(II)— 
8
(i) by striking item (bb); and 
9
(ii) by redesignating items (cc) and 
10
(dd) as items (bb) and (cc), respectively; 
11
and 
12
(B) by adding at the end the following: 
13
‘‘(v) FIRST APPLICANT DEFINED.—As used in 
14
this subsection, the term ‘first applicant’ means an 
15
applicant— 
16
‘‘(I)(aa) that, on the first day on which a 
17
substantially complete application containing a 
18
certification 
described 
in 
paragraph 
19
(2)(A)(vii)(IV) is submitted for approval of a 
20
drug, submits a substantially complete applica-
21
tion that contains and lawfully maintains a cer-
22
tification described in paragraph (2)(A)(vii)(IV) 
23
for the drug; and 
24
00:08 Mar 16, 2019
H1506
3 
•HR 1506 IH
‘‘(bb) that has not entered into a disquali-
1
fying 
agreement 
described 
under 
clause 
2
(vii)(II); or 
3
‘‘(II)(aa) for the drug that is not described 
4
in subclause (I) and that, with respect to the 
5
applicant and drug, each requirement described 
6
in clause (vi) is satisfied; and 
7
‘‘(bb) that has not entered into a disquali-
8
fying 
agreement 
described 
under 
clause 
9
(vii)(II). 
10
‘‘(vi) REQUIREMENT.—The requirements de-
11
scribed in this clause are the following: 
12
‘‘(I) The applicant described in clause 
13
(v)(II) submitted and lawfully maintains a cer-
14
tification described in paragraph (2)(A)(vii)(IV) 
15
or 
a 
statement 
described 
in 
paragraph 
16
(2)(A)(viii) for each unexpired patent for which 
17
a first applicant described in clause (v)(I) had 
18
submitted a certification described in paragraph 
19
(2)(A)(vii)(IV) on the first day on which a sub-
20
stantially complete application containing such 
21
a certification was submitted. 
22
‘‘(II) With regard to each such unexpired 
23
patent for which the applicant described in 
24
clause (v)(II) submitted a certification de-
25
00:08 Mar 16, 2019
H1506
4 
•HR 1506 IH
scribed in paragraph (2)(A)(vii)(IV), no action 
1
for patent infringement was brought against 
2
such applicant within the 45-day period speci-
3
fied in paragraph (5)(B)(iii); or if an action 
4
was brought within such time period, such an 
5
action was withdrawn or dismissed by a court 
6
(including a district court) without a decision 
7
that the patent was valid and infringed; or if an 
8
action was brought within such time period and 
9
was not withdrawn or so dismissed, such appli-
10
cant has obtained the decision of a court (in-
11
cluding a district court) that the patent is in-
12
valid or not infringed (including any substantive 
13
determination that there is no cause of action 
14
for patent infringement or invalidity, and in-
15
cluding a settlement order or consent decree 
16
signed and entered by the court stating that the 
17
patent is invalid or not infringed). 
18
‘‘(III) If an applicant described in clause 
19
(v)(I) has begun commercial marketing of such 
20
drug, the applicant described in clause (v)(II) 
21
does not begin commercial marketing of such 
22
drug until the date that is 30 days after the 
23
date on which the applicant described in clause 
24
(v)(I) began such commercial marketing.’’. 
25
00:08 Mar 16, 2019
H1506
5 
•HR 1506 IH
(2) 
CONFORMING
AMENDMENT.—Section 
1
505(j)(5)(D)(i)(IV) 
of 
such 
Act 
(21 
U.S.C. 
2
355(j)(5)(D)(i)(IV)) is amended by striking ‘‘The 
3
first applicant’’ and inserting ‘‘The first applicant, 
4
as defined in subparagraph (B)(v)(I),’’. 
5
(b) APPLICABILITY.—The amendments made by sub-
6
section (a) shall apply only with respect to an application 
7
filed under section 505(j) of the Federal Food, Drug, and 
8
Cosmetic Act (21 U.S.C. 355(j)) to which the amendments 
9
made by section 1102(a) of the Medicare Prescription 
10
Drug, Improvement, and Modernization Act of 2003 (Pub-
11
lic Law 108–173) apply. 
12
SEC. 3. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS RE-
13
GARDING AGREEMENTS TO DEFER COMMER-
14
CIAL MARKETING. 
15
(a) AMENDMENTS TO FEDERAL FOOD, DRUG, AND 
16
COSMETIC ACT.— 
17
(1) LIMITATIONS ON AGREEMENTS TO DEFER 
18
COMMERCIAL
MARKETING
DATE.—Section 
19
505(j)(5)(B) of the Federal Food, Drug, and Cos-
20
metic Act (21 U.S.C. 355(j)(5)(B)), as amended by 
21
section 2, is further amended by adding at the end 
22
the following: 
23
‘‘(vii) AGREEMENT
BY
FIRST
APPLICANT
TO 
24
DEFER
COMMERCIAL
MARKETING; LIMITATION
ON 
25
00:08 Mar 16, 2019
H1506
6 
•HR 1506 IH
ACCELERATION
OF
DEFERRED
COMMERCIAL
MAR-
1
KETING DATE.— 
2
‘‘(I) AGREEMENT TO DEFER APPROVAL OR 
3
COMMERCIAL
MARKETING
DATE.—An agree-
4
ment described in this subclause is an agree-
5
ment between a first applicant and the holder 
6
of the application for the listed drug or an 
7
owner of one or more of the patents as to which 
8
any applicant submitted a certification quali-
9
fying such applicant for the 180-day exclusivity 
10
period whereby that applicant agrees, directly 
11
or indirectly, (aa) not to seek an approval of its 
12
application that is made effective on the earliest 
13
possible date under this subparagraph, subpara-
14
graph (F) of this paragraph, section 505A, or 
15
section 527, (bb) not to begin the commercial 
16
marketing of its drug on the earliest possible 
17
date after receiving an approval of its applica-
18
tion that is made effective under this subpara-
19
graph, subparagraph (F) of this paragraph, sec-
20
tion 505A, or section 527, or (cc) to both items 
21
(aa) and (bb). 
22
‘‘(II) AGREEMENT THAT DISQUALIFIES AP-
23
PLICANT FROM FIRST APPLICANT STATUS.—An 
24
agreement described in this subclause is an 
25
00:08 Mar 16, 2019
H1506
7 
•HR 1506 IH
agreement between an applicant and the holder 
1
of the application for the listed drug or an 
2
owner of one or more of the patents as to which 
3
any applicant submitted a certification quali-
4
fying such applicant for the 180-day exclusivity 
5
period whereby that applicant agrees, directly 
6
or indirectly, not to seek an approval of its ap-
7
plication or not to begin the commercial mar-
8
keting of its drug until a date that is after the 
9
expiration of the 180-day exclusivity period 
10
awarded to another applicant with respect to 
11
such drug (without regard to whether such 180- 
12
day exclusivity period is awarded before or after 
13
the date of the agreement). 
14
‘‘(viii) LIMITATION ON ACCELERATION.—If an 
15
agreement described in clause (vii)(I) includes more 
16
than 1 possible date when an applicant may seek an 
17
approval of its application or begin the commercial 
18
marketing of its drug— 
19
‘‘(I) the applicant may seek an approval of 
20
its application or begin such commercial mar-
21
keting on the date that is the earlier of— 
22
‘‘(aa) the latest date set forth in the 
23
agreement on which that applicant can re-
24
ceive an approval that is made effective 
25
00:08 Mar 16, 2019
H1506
8 
•HR 1506 IH
under this subparagraph, subparagraph 
1
(F) of this paragraph, section 505A, or 
2
section 527, or begin the commercial mar-
3
keting of such drug, without regard to any 
4
other provision of such agreement pursu-
5
ant to which the commercial marketing 
6
could begin on an earlier date; or 
7
‘‘(bb) 180 days after another first ap-
8
plicant begins commercial marketing of 
9
such drug; and 
10
‘‘(II) the latest date set forth in the agree-
11
ment on which that applicant can receive an ap-
12
proval that is made effective under this sub-
13
paragraph, subparagraph (F) of this paragraph, 
14
section 505A, or section 527, or begin the com-
15
mercial marketing of such drug, without regard 
16
to any other provision of such agreement pursu-
17
ant to which commercial marketing could begin 
18
on an earlier date, shall be the date used to de-
19
termine whether an applicant is disqualified 
20
from first applicant status pursuant to clause 
21
(vii)(II).’’. 
22
(2) NOTIFICATION OF FDA.—Section 505(j) of 
23
such Act (21 U.S.C. 355(j)) is amended by adding 
24
at the end the following: 
25
00:08 Mar 16, 2019
H1506
9 
•HR 1506 IH
‘‘(11)(A) The holder of an abbreviated application 
1
under this subsection shall submit to the Secretary a noti-
2
fication that includes— 
3
‘‘(i)(I) the text of any agreement entered into 
4
by 
such 
holder 
described 
under 
paragraph 
5
(5)(B)(vii)(I); or 
6
‘‘(II) if such an agreement has not been re-
7
duced to text, a written detailed description of such 
8
agreement that is sufficient to disclose all the terms 
9
and conditions of the agreement; and 
10
‘‘(ii) the text, or a written detailed description 
11
in the event of an agreement that has not been re-
12
duced to text, of any other agreements that are con-
13
tingent upon, provide a contingent condition for, or 
14
are otherwise related to an agreement described in 
15
clause (i). 
16
‘‘(B) The notification described under subparagraph 
17
(A) shall be submitted not later than 10 business days 
18
after execution of the agreement described in subpara-
19
graph (A)(i). Such notification is in addition to any notifi-
20
cation required under section 1112 of the Medicare Pre-
21
scription Drug, Improvement, and Modernization Act of 
22
2003. 
23
‘‘(C) Any information or documentary material filed 
24
with the Secretary pursuant to this paragraph shall be ex-
25
00:08 Mar 16, 2019
H1506
10 
•HR 1506 IH
empt from disclosure under section 552 of title 5, United 
1
States Code, and no such information or documentary ma-
2
terial may be made public, except as may be relevant to 
3
any administrative or judicial action or proceeding. Noth-
4
ing in this paragraph is intended to prevent disclosure to 
5
either body of the Congress or to any duly authorized com-
6
mittee or subcommittee of the Congress.’’. 
7
(3) PROHIBITED ACTS.—Section 301(e) of such 
8
Act (21 U.S.C. 331(e)) is amended by striking ‘‘505 
9
(i) or (k)’’ and inserting ‘‘505 (i), (j)(11), or (k)’’. 
10
(b) INFRINGEMENT OF PATENT.—Section 271(e) of 
11
title 35, United States Code, is amended by adding at the 
12
end the following: 
13
‘‘(7) The exclusive remedy under this section for an 
14
infringement of a patent for which the Secretary of Health 
15
and Human Services has published information pursuant 
16
to subsection (b)(1) or (c)(2) of section 505 of the Federal 
17
Food, Drug, and Cosmetic Act shall be an action brought 
18
under this subsection within the 45-day period described 
19
in subsection (j)(5)(B)(iii) or (c)(3)(C) of section 505 of 
20
the Federal Food, Drug, and Cosmetic Act.’’. 
21
(c) APPLICABILITY.— 
22
(1) LIMITATIONS
ON
ACCELERATION
OF
DE-
23
FERRED
COMMERCIAL
MARKETING
DATE.—The 
24
00:08 Mar 16, 2019
H1506
11 
•HR 1506 IH
amendment made by subsection (a)(1) shall apply 
1
only with respect to— 
2
(A) an application filed under section 
3
505(j) of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 355(j)) to which the 
5
amendments made by section 1102(a) of the 
6
Medicare Prescription Drug, Improvement, and 
7
Modernization Act of 2003 (Public Law 108– 
8
173) apply; and 
9
(B) an agreement described under section 
10
505(j)(5)(B)(vii)(I) of the Federal Food, Drug, 
11
and Cosmetic Act (as added by subsection 
12
(a)(1)) executed after the date of enactment of 
13
this Act. 
14
(2) NOTIFICATION OF FDA.—The amendments 
15
made by paragraphs (2) and (3) of subsection (a) 
16
shall apply only with respect to an agreement de-
17
scribed under section 505(j)(5)(B)(vii)(I) of the 
18
Federal Food, Drug, and Cosmetic Act (as added by 
19
subsection (a)(1)) executed after the date of enact-
20
ment of this Act. 
21
Æ 
00:08 Mar 16, 2019
H1506
